Qiagen N.V. $QGEN Stock Holdings Lifted by Gateway Investment Advisers LLC

Gateway Investment Advisers LLC lifted its position in Qiagen N.V. (NYSE:QGEN) by 105.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 55,094 shares of the company’s stock after acquiring an additional 28,313 shares during the period. Gateway Investment Advisers LLC’s holdings in Qiagen were worth $2,478,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in QGEN. Danske Bank A S purchased a new position in shares of Qiagen in the third quarter worth approximately $36,000. Smartleaf Asset Management LLC increased its position in shares of Qiagen by 1,383.3% in the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after acquiring an additional 830 shares in the last quarter. Allworth Financial LP increased its position in shares of Qiagen by 23.2% in the third quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock worth $61,000 after acquiring an additional 256 shares in the last quarter. Advisory Services Network LLC purchased a new position in shares of Qiagen in the third quarter worth approximately $64,000. Finally, Jones Financial Companies Lllp increased its position in shares of Qiagen by 64.0% in the third quarter. Jones Financial Companies Lllp now owns 1,610 shares of the company’s stock worth $71,000 after acquiring an additional 628 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Performance

QGEN stock opened at $33.05 on Friday. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $6.81 billion, a price-to-earnings ratio of 17.26, a P/E/G ratio of 3.34 and a beta of 0.64. Qiagen N.V. has a 12 month low of $32.92 and a 12 month high of $57.81. The firm has a 50 day moving average of $40.93 and a two-hundred day moving average of $46.38.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, May 6th. The company reported $0.54 EPS for the quarter, hitting the consensus estimate of $0.54. The company had revenue of $492.32 million during the quarter, compared to the consensus estimate of $496.15 million. Qiagen had a net margin of 19.16% and a return on equity of 14.09%. During the same period in the previous year, the firm posted $0.56 earnings per share. As a group, equities analysts anticipate that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

QGEN has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $43.00 target price on shares of Qiagen in a research report on Thursday, April 30th. Citigroup dropped their target price on shares of Qiagen from $55.00 to $38.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 29th. Stifel Nicolaus set a $50.00 target price on shares of Qiagen and gave the stock a “hold” rating in a research report on Friday, February 6th. Barclays set a $38.00 target price on shares of Qiagen and gave the stock an “equal weight” rating in a research report on Wednesday, April 29th. Finally, TD Cowen reaffirmed a “hold” rating and set a $40.00 price objective (down from $46.00) on shares of Qiagen in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $46.38.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.